Determination of unbound platinum after oxaliplatin administration: Comparison of currently available methods and influence of various parameters

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 223-228

  Gamelin, E ^a   Boisdron Celle, M ^a   Lebouil, A ^b   Turcant, A ^b   Cailleux, A ^b   Krikorian, A ^e   Brienza, S ^e   Cvitkovic, E ^c   Larra, F ^a   Robert, J ^d   Allain, P ^a  

^a CENTRE PAUL PAPIN   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d INSTITUT BERGONIÉ   (France)

^e DEBIOPHARM France   (France)

Author keywords

Oxaplatin; Platinum compounds; Protein binding

Indexed keywords

OXALIPLATIN; PLATINUM;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; DEVICE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; TECHNIQUE; ULTRACENTRIFUGATION;

EID: 7144251860     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00004     Document Type: Article

References (22)

1. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 1992; 23: 449-68.
2. Verbeck RK, Cardinal JA. Plasma protein binding of salicylic acid, phenytoïn, chlorpromazine, propranolol and pethidine using equilibrium dialysis and ultracentrifugation. Arzneim Forsch 1985; 35: 903-6.
3. Kurz H, Trunk H, Weitz B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneim Forsch 1977; 27: 1373-9.
4. Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985; 151: 193-216.
5. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV. Pharmacokinetics and protein binding of cisdiamminedichloroplatinum(II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 1980; 5: 21-6.
6. Gamelin E, Allain P, Maillart P, et al. Long-term pharmacokinetic behaviour of platinum after cisplatin administration. Cancer Chemother Pharmacol 1995; 37: 97-102.
7. Campbell AH, Kalman SM, Jacobs C. Plasma platinum levels: relationship to platinum dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 169-72.
8. Desoize B, Maréchal F, Millard H, Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 1991; 45: 203-7.
9. Matsushita Y, Moriguchi I. Measurement of protein binding by ultracentrifugation. Chem Pharm Bull 1985; 33: 2948-55.
10. Vermorken JB, van der Vijgh WJF, van der Klein I, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986; 39: 136-44.
11. Momhurg R, Bourdeaux M, Sarrazin M, Roux F, Briand C. In vitro plasma binding of some second generation antitumor platinum complexes. Eur J Drug Metab Pharmacokinet 1985; 10: 77-83.
12. Gamelin E, Le Bouil A, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil to colorectal cancer patients. Clin Cancer Res 1997; 3: 891-9.
13. Boughattas NA, Hecquet B, Fournier C, et al. Comparative pharmacokinctics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos 1994; 15: 761-73.
14. Allain P, Berre S, Mauras Y, Le Bouil A. Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrometry 1992; 21: 141-3.
15. McKay K. New techniques in the pharmacokinetic analysis of cancer drugs. The ultratrace determination of platinum in biological samples by inductively coupled plasma mass spectrometry. Cancer Surv 1993; 17: 407-14.
16. Tothill P, Matheson LM, Smyth JF, McKay K. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry. J Anal Atomic Spectr 1990; 5: 619-22.
17. Manaka R, Wolf W. Distribution of cisplatin in blood. Chem-Biol Interact 1978; 22: 353-8.
18. Repta AJ, Long DF. Reactions of cisplatin with human plasma and plasma fractions. In: Repto AJ, Long DE, eds. Cisplatin. New York: Academic Press 1980; 18: 285-304.
19. Tosetti F, Rocco M, Fulco RA, et al. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. Anticancer Res 1988; 8: 381-6.
20. Dalez-Yates PT. The metabolites of platinum antitumor drugs and their biological significance. In: McBrien DCH, Slater TF, eds. Biochemical mechanisms of platinum antitumor drugs. Oxford: IRL 1986: 121-46.
21. 14C-carboplatin. Cancer Chemother Pharmacol 1987; 20: 271-6.
22. Elferink F, van der Vijgh WJF, Klein I, Vermorken JB, Gall E, Pinedo HM. Pharmacokinetics of carboplatin after iv administration. Cancer Treat Rep 1987; 71: 1231-7.